A drug that has gained worldwide attention for treating diabetes and helping people lose weight has now been tested as a possible treatment for Alzheimer’s disease. However, new research shows that it may not work for this purpose as scientists had hoped.
The drug is called oral semaglutide. It belongs to a group of medicines known as GLP-1 receptor agonists. These drugs are commonly used to treat type 2 diabetes and are also widely known for their role in weight loss.
In recent years, researchers began to wonder whether these drugs might also help protect the brain and slow down diseases like Alzheimer’s.
Alzheimer’s disease is the most common form of dementia. It mainly affects older adults and leads to memory loss, confusion, and changes in behavior. As the disease progresses, it becomes harder for people to carry out daily activities. Because there is currently no cure, scientists are actively searching for treatments that can slow its progression.
Earlier studies had raised hope that GLP-1 drugs like semaglutide might help. Research in animals and small human studies suggested that these drugs could reduce inflammation in the brain, improve blood flow, and protect brain cells. Some studies in people with diabetes and obesity also hinted that GLP-1 drugs might lower the risk of developing dementia.
To test this idea more carefully, scientists carried out two large clinical trials called EVOKE and EVOKE+. These were Phase III randomized controlled trials, which are considered the most reliable type of study for testing whether a treatment works.
The trials included around 3,800 people between the ages of 55 and 85. All participants had been diagnosed with Alzheimer’s disease at an early stage and had mild symptoms.
The participants were randomly divided into two groups. One group received a daily dose of oral semaglutide, up to 14 milligrams, while the other group received a placebo, which is a pill with no active medicine.
The study lasted for two years, and some participants continued for an additional year. During this time, researchers carefully tracked changes in memory, thinking ability, and daily function to see whether the drug had any effect on the progression of the disease.
At the end of the study, the results were clear. There was no meaningful difference between the group taking semaglutide and the group taking the placebo. Both groups showed similar levels of disease progression over time. Even among those who continued treatment for an extra year, the results remained the same.
Interestingly, in a smaller group of about 200 participants, the drug did lead to changes in certain biological markers linked to Alzheimer’s disease. These markers are often used by scientists to study what is happening in the brain. However, these changes did not lead to any real improvement in symptoms or slowing of the disease.
The findings were published in The Lancet, one of the world’s leading medical journals. This makes the study especially important, as it provides strong evidence based on a large number of patients.
These results are disappointing for researchers and patients who had hoped that semaglutide might offer a new way to treat Alzheimer’s. However, the study also provides valuable information. It shows that even if a drug affects certain biological processes, this does not always mean it will improve a person’s condition.
In reviewing the study, there are several strengths. The large number of participants and the long follow-up period make the results reliable. The use of randomized controlled trials also reduces bias and increases confidence in the findings.
At the same time, there are some limitations. The study focused only on patients with mild Alzheimer’s disease, so it is not clear whether the drug might have different effects at other stages. In addition, while the drug did not slow disease progression, the changes in biological markers suggest that it may still have some effect on the brain that needs further study.
Overall, this research highlights how complex Alzheimer’s disease is and how challenging it is to find effective treatments. While semaglutide may not be the answer, scientists will continue to explore other options in the search for ways to protect brain health.
If you care about Alzheimer’s disease, please read studies about the protective power of dietary antioxidants against Alzheimer’s, and eating habits linked to higher Alzheimer’s risk.
For more health information, please see recent studies that oral cannabis extract may help reduce Alzheimer’s symptoms, and Vitamin E may help prevent Parkinson’s disease.
Copyright © 2026 Knowridge Science Report. All rights reserved.
